Company Overview of Celtaxsys, Inc.
Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded in 2007 and is based in Atlanta, Georgia.
201 17th Street
Atlanta, GA 30363
Founded in 2007
Key Executives for Celtaxsys, Inc.
Chief Executive Officer, President and Director
Founder and Chief Financial Officer
Vice President of Operations
Compensation as of Fiscal Year 2015.
Celtaxsys, Inc. Key Developments
Celtaxsys Begins US Enrollment for Phase 2 Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis
Oct 8 15
Celtaxsys announced the commencement of the US arm of an international phase 2 clinical trial for its compound, acebilustat, in patients with cystic fibrosis (CF). The study will be conducted at approximately 60 sites in the United States and European Union, with the EU sites anticipated to begin enrollment early 2016. This clinical trial testing once-daily oral acebilustat treatment over 48 weeks could be the first to establish proof-of-concept for an anti-inflammatory treatment specifically designed to prevent long-term loss of lung function in CF patients. The study will test once daily oral doses of 50 mg and 100 mg acebilustat against placebo on top of background therapy in adult CF patients. Acebilustat is a first-in-class neutrophil modulator that controls a key inflammatory signal overexpressed in CF and other orphan inflammatory diseases. Acebilustat has been granted orphan drug status for the treatment of CF in the US and the EU. Results from initial clinical studies in CF patients demonstrated acebilustat's ability to moderate the over-activated inflammatory response in CF, decreasing neutrophils in the lung by 65% and decreasing damaging neutrophil elastase in just two weeks of treatment. Acebilustat did this without jeopardizing the patient's immune response to infection. Importantly, acebilustat treatment is applicable to all CF patients irrespective of their gene mutation and can be used on top of background therapy, including Kalydeco and Orkambi.
Celtaxsys, Inc. Gains U.S. Food and Drug Administration Clearance for Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis
Jul 6 15
Celtaxsys, Inc. announced that it has gained clearance from the U.S. Food and Drug Administration (FDA) to begin a Phase 2 clinical trial of its drug candidate, acebilustat (CTX-4430), in adult CF patients in the US. The regulatory submissions to the health authorities in Europe will be filed soon after. This groundbreaking clinical study, testing the lung function preservation effects of once-daily oral acebilustat treatment over 48 weeks, was designed in consultation with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT). The trial will be conducted in partnership with the CFFT and is partially funded by the $5 million research award granted by the CFFT to Celtaxsys earlier in 2015.
Celtaxsys, Inc. Announces Board Appointments
Jun 8 15
Celtaxsys, Inc. announced the successful completion of a $40 million Series D financing led by Domain Partners VIII. Additional investors in the financing include Lumira Capital, RMI Partners, Masters Capital Management and the Georgia Research Alliance Venture Fund. In conjunction with the financing, Nicole Vitullo, Partner at Domain Associates, Gerry Brunk, Managing Director at Lumira Capital, and Maxim Gorbachev, Partner at RMI Partners will join the company's board of directors at this important juncture for the company.
Similar Private Companies By Industry
Recent Private Companies Transactions
June 3, 2015